Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Roche's tPSA and fPSA tests:

This article was originally published in Clinica

Executive Summary

Roche Diagnostics has gained US FDA approval for two prostate specific antigen (PSA) tests for prostate cancer. The Elecsys total PSA (tPSA) and Elecsys free PSA are automated blood tests that are run on the company's Elecsys immunoassay systems. The tPSA is a prostate cancer screening test for use in conjunction with a digital rectal examination (DRE). The fPSA is to be used with the tPSA test to calculate the ratio of fPSA to tPSA, a figure useful in distinguishing prostate cancer from benign conditions in men with an elevated PSA but a normal DRE.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel